Clinical Trials for Hepatocellular Carcinoma Non-resectable

Find clinical trials for hepatocellular carcinoma non-resectable. Discover research opportunities and treatment options in your area.

28 Active Trials Found

Showing 28 trials on this page

Page 2 of 2

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma

NCT ID: NCT05717738

This clinical trial is investigating a new treatment for patients with advanced liver cancer, known as hepatocellular carcinoma (HCC), that cannot be surgically removed or treated by other methods....

Recruiting

Type: observational Locations: Wuhan, Hubei, China, Quanzhou, Fujian, China +2 more

Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC

NCT ID: NCT06397222

This clinical trial is studying a combination of three treatments—sintilimab, bevacizumab, and selective internal radiation therapy (SIRT)—for patients with intermediate to advanced liver cancer (h...

Recruiting

Phase: PHASE2 Type: interventional Locations: Guangzhou, Guangdong, China

Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.

NCT ID: NCT06375486

This clinical trial is studying a new treatment for patients with unresectable hepatocellular carcinoma (HCC), which is a type of liver cancer that cannot be removed through surgery. The treatment ...

Recruiting

Phase: PHASE2 Type: interventional Locations: Tianjin, Tianjin, China, Tianjin, Tianjin, China

Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

NCT ID: NCT06040177

This clinical trial is investigating a new treatment approach for patients with a specific type of liver cancer called unresectable hepatocellular carcinoma, particularly those with a blockage in t...

Recruiting

Phase: PHASE1 Type: interventional Locations: Nanning, Guangxi, China

Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC

NCT ID: NCT05985798

This clinical trial is comparing two treatment options for patients with advanced liver cancer known as hepatocellular carcinoma (HCC) that cannot be surgically removed. The trial is specifically l...

Recruiting

Phase: PHASE3 Type: interventional Locations: Guangzhou, Guangdong, China

Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC

NCT ID: NCT05608200

This clinical trial is studying a combination treatment for patients with advanced liver cancer, known as hepatocellular carcinoma (HCC), that cannot be surgically removed. The researchers want to ...

Recruiting

Phase: PHASE3 Type: interventional Locations: Guangzhou, Guangdong, China, Guangzhou, Guangdong, China

Individualized Dosimetry for Holmium-166-radioembolization in Patients With Unresectable Hepatocellular Carcinoma

NCT ID: NCT05114148

This clinical trial is studying a new treatment option for patients with unresectable hepatocellular carcinoma (HCC), a type of liver cancer that cannot be surgically removed. The treatment being t...

Recruiting

Phase: NA Type: interventional Locations: Utrecht, , Netherlands

Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

NCT ID: NCT05608213

This clinical trial is studying a new treatment approach for patients with hepatocellular carcinoma (HCC), a type of liver cancer that cannot be surgically removed and has not responded to a previo...

Recruiting

Phase: PHASE3 Type: interventional Locations: Guangzhou, Guangdong, China, Guangzhou, Guangdong, China

Related Conditions

Breast Cancer View clinical trials → Stroke View clinical trials → Obesity View clinical trials → Cancer View clinical trials → Healthy View clinical trials → Prostate Cancer View clinical trials →

Search All Trials Browse All Conditions